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Abstract: 
Recently, the use of proton beams in cancer therapy is spreading out and tumour treatment modalities 
combining radiosensitizing chemical agents with irradiation are under investigation in order to achieve 
greater tumour local control and reduce the probability of distant failures. The combined treatment modality 
of radiation and the clinically relevant microtubule-stabilizing compound Epothilone B is a promising 
approach for anticancer therapy. In the present  study, we investigated the cytotoxicity of a Spread Out Bragg 
Peak (SOBP) proton beam , as well as of 6 MV photons, in human glioblastoma (U251 MG) and lung 
adenocarcinoma (A549) cells pretreated for 24 h, or not,  with Epothilone B at concentrations of 0.125 and 
0.075 nM respectively. Proton irradiation was performed at the middle position of an actively modulated  
SOBP ( 12 -18 cm depth in water) and cell survival was evaluated by colony forming assay.  
For both cell lines, survival curves after proton or photon irradiation alone showed a linear quadratic 
behaviour with a proton RBE (Relative Biological Effectiveness), compared with photons at 10% survival, 
of 1.5 ± 0.2 . Treatment of the cells with Epothilone B at subnanomolar concentration has an anticlonogenic 
effect. Furthermore, differently from the results found with radiation alone, the survival curves for the 
combined treatment Epothilone B - radiation showed a linear trend and analysis of the interaction of the two 
cytotoxic agents indicated a slight synergism. 
These data provide a radiobiological basis for further experiments, as well as clinical studies. 
 
 
 
 
 
 
 
 
 
 
 
 3 
1. Introduction  
Lung cancer remains the most common cause of cancer death  in western countries (Jemal et al 2009, 
Ferlay et al 2008). Lung adenocarcinoma is a kind of non-small cell lung cancer (NSCLC) that affects 
the epithelial cells of the bronchial tube and it is the most common lung neoplasia in non-smokers. 
Recently, new treatment modalities, such as concurrent chemoradiotherapy (O’ Rourke et al 2010, 
Eberhardt 2015, Bao et al 2015) and particle radiotherapy (Liao et al 2011, Grutters et al 2010), have 
been introduced for patients with NSCLC. The rationale for combining chemotherapy and radiotherapy 
is to exploit the benefits of radiotherapy in terms of sensitising tumour to radiation locally and reducing 
the risk of distant failures. Many studies have evaluated the combined effect of radiation and 
chemotherapy using photons. Combined radio-chemotherapy protocols are already used in the treatment 
of many cancers, such as glioblastoma multiforme, pancreas cancer or non-small-cell lung cancer 
(Durante 2014, Albain et al 2009).  
Glioblastomas (GBMs) are the most frequent primary tumours of the central nervous system. They are 
very aggressive, highly angiogenic and typically associated with very poor prognosis. One of the main 
biological features of GBM is the local invasion of the surrounding brain tissue. Such an invasive 
behaviour represents the greatest obstacle to an effective treatment of this kind of brain tumour (Pagano 
et al 2012). Currently, the standard approach to glioblastoma treatment combines surgical resection, 
chemotherapy and radiotherapy. Beyond initial surgery aimed at reducing the tumour burden, the 
mainstay of therapy is based on the use of concurrent and adjuvant Temozolomide (TMZ, a DNA-
binding agent) in conjunction with radiotherapy (Stupp et al 2009, Sathornsumetee and Rich 2008, 
Mirmanoff et al 2006, Stupp et al 2015). 
An increasing number of studies are investigating the interaction of drugs with charged particles, 
namely carbon ions and protons, which are very promising for the treatment of radioresistant tumours 
due to their dosimetric and radiobiological properties (Combs et al 2012, Kitabayashi et al 2006, El 
Shafie et al 2013, Schlaich et al 2013, Loeffler and Durante 2013, Chalmers et al 2009, Barazzuol et al 
2012). For protons, the major difference with photon radiotherapy is the spatial distribution of the 
absorbed dose: using charged particles for the treatment of tumour close to vital and radiosensitive 
organs, the dose deposited to the surrounding normal tissue can be reduced and therefore the dose to the 
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tumour escalated. Thus, proton beam therapy is suitable when normal tissue sparing is a priority such as 
in the treatment of lung cancer, given the proximity to the oesophagus, the heart and the spinal cord. 
The first study on proton therapy with concurrent chemotherapy with carboplatin and paclitaxel for 
unresectable stage III non-small cell lung cancer was reported by Chang (Chang et al 2011) with good 
results in terms of patients median survival and toxicity. As far as we know, very few data are available 
on the effect of proton irradiation alone or in combination with chemotherapy in patients with GBM 
(Combs et al 2010, Rieken et al 2012, Fitzek et al 1999, Suit et al 2008). 
The research of drugs to be used as radiosensitisers has led to the discovery of a new class of 
Microtubule-stabilizing agents (MSAs): the Epothilones. MSAs, such as the widespread Taxanes, are 
able to interfere with the mitotic spindle formation, leading to cell cycle arrest in the G2/M phase, the 
most radiosensitive phase in the cell cycle (Bollag et al 1995, Altmann et al 2000, Altmann and Gertsh 
2007, Agrawal et al 2003, Pawlik and Keyomarsi 2004, Roher Bley et al 2013). Epothilone B 
(Patupilone, EPO906) has been used in several clinical trials (Vansteenkiste et al 2007, Oehler et al 
2012) and has been tested as a chemotherapy drug both in vitro and in vivo, even in combination with 
photon radiotherapy (Hofstetter et al 2005, Kim et al 2005). A recent phase I trial investigated 
Epothilone B in conjunction with irradiation in patients with recurrent glioma (Fogh et al 2010). The 
ability of Epothilone B to cross the blood-brain barrier and to retain in brain tissue (O’Reilly et al 2008) 
makes it a very powerful and promising chemotherapeutical  agent for brain malignancies. Epothilone B 
has shown antivascular and antiangiogenic effects (Ferretti et al 2005, Bocci et al 2002) and the ability 
to effectively inhibit cells’ migration at non-cytotoxic concentration (Pagano et al 2012, Furmanova-
Hollenstein et al 2013). It was also demonstrated that Epothilone B reduces DNA repair capability of 
tumour cells (Baumgart et al 2012, 2015) . 
The purpose of this study was to investigate the effect of Epothilone B combined with proton or photon 
beams on cultured human tumour lung cells, A549, and glioblastoma multiforme cells, U251MG. Cell 
clonogenic survival was assessed after irradiation alone or combined with Epothilone B, in order to 
determine the interaction mechanism between radiation and drug.  
Protons RBE (Relative Biological Effectiveness) for A549 and U251MG cells clonogenic survival was 
determined by comparing cell survival data after proton and photon irradiation. Indeed, although proton 
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therapy is a consolidate alternative to photon radiotherapy for some types of cancer  and  an RBE of 1.1 
has been recommended for clinical use, proton RBE values reported in literature show large fluctuations  
(see for a review Paganetti 2014, Jones 2016). Furthermore data published in recent years on several 
responses of cells irradiated with protons and, for comparison , to photons (see for a review Tommasino 
and Durante 2015), have indicated that RBE in proton therapy is still an issue that needs further 
investigation. 
2. Methods 
2.1. Cell lines and culture  
A549 and U251MG cultures were supplied by the ICLC (Interlab Cell Line Collection, Genova, Italy). 
A549 and U251MG cells were maintained at 37°C in humidified atmosphere containing 5% CO2 in air 
as exponentially growing cultures respectively in Dulbecco Modified Eagles Medium (DMEM, Sigma -
Aldrich) and Eagles Minimum Essential Medium (EMEM, Sigma-Aldrich), both supplemented with 
10% fetal bovine serum (FBS, Sigma-Aldrich) and gentamicin (50 μg/ml) (Sigma-Aldrich). In these 
conditions the doubling time were 21 ± 0.2 hours and 24 ± 1 hours for A549 and U251MG 
respectively. All cell lines were confirmed to be Mycoplasma-free before use. The cells were plated 
in T25 flasks ( 10
5 
cells/ flask) 72 h before the irradiation. 
2.2  Epothilone B 
Epothilone B (Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) to generate a 10µM stock 
solution. The stock solution was then diluted in medium at appropriate concentrations. The final DMSO 
concentrations were less then 0.1%, a concentration which had no effect on cell survival. For the 
combined treatments, 24 h before the irradiation Epothilone B was added to the samples  using equitoxic 
concentrations for the two cell lines (40% clonogenic survival, 0.075 nM and 0.125 nM respectively for 
A549 and U251MG cells,  see 3.1). The drug was removed after 24 h , just before the irradiation. 
2.3 Irradiation  
Cell irradiation with protons was performed using the synchrotron-based clinical scanning beams (fixed 
horizontal beam line) at the Centro Nazionale di Adroterapia Oncologica (CNAO, PAVIA) (Mirandola 
et al. 2015, Rossi 2015). The flasks were placed vertically inside a water phantom put at the isocenter 
on the treatment table, at the depth of 15 cm, corresponding to the mid Spread-Out Bragg Peak (SOBP). 
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The SOBP (6 cm width, from 12 to 18 cm depth in water) was achieved with active beam energy 
modulation, using 16 different energies (131.5-164.8 MeV). The flasks were put in the centre of an 
uniformly scanned 10x10 cm
2
 field size (scanning step equal to 3 mm). Protons dose-averaged Linear 
Energy Transfer (LET) in the mid SOBP, evaluated with Monte Carlo FLUKA simulation, was 3.6 
keV/μm. Samples were irradiated at different doses (0-5 Gy). 
Photon beam irradiation of cell cultures was performed using a 6 MV linear accelerator (VARIAN 
Clinac 2100C, Varian Medical Systems, Palo Alto, USA) at the Fondazione IRCCS Istituto Nazionale 
dei Tumori, Milano. The flasks containing the cells were placed horizontally at the isocentre in a water 
phantom at 5 cm depth and were irradiated using a vertical beam 20x20 cm
2
 field. Samples were 
irradiated at different doses (0-7 Gy).  
For both the beams all the flasks were irradiated completely filled with medium.   
2.4. Clonogenic Assay. 
The assessment of the effect of the combination of Epothilone B and radiation ( photons or protons) was 
performed using the clonogenic assay. Retention of reproductive integrity, i.e. the ability of a cell to 
produce a viable colony containing at least 50 cells,  is the accepted gold standard  for measuring the 
radiosensitivity  of a cell population ( IAEA 2010 ). Furthermore clonogenic survival has a particular 
relevance to the radiotherapy of tumours as for a tumour to be eradicated it is necessary that the cells are 
made unable to divide and cause further growth of the malignancy ( Hall and Giaccia  2006). 
To measure cell clonogenic survival, cells were detached from the flask immediately after irradiation 
using 0.25% Trypsin-EDTA, counted, reseeded in 5 T25 flasks for each dose/ treatment  at suitable 
concentration and incubated for about 13 days. Incubation time intervals for clonogenic survival of 
these human  cell lines reported in the literature are between 10 and 14 days (Baumgart et al 2012  , 
Combs et al 2012, Rohrer Bley et al 2009 ). The cells were then fixed with ethanol and stained with 
10% Giemsa solution and colonies consisting of more than 50 cells were scored as survivors. Surviving 
fractions relative to the untreated samples were determined . 
2.5. Analysis of radiation-drug interaction  
Survival curves obtained with radiation alone and in conjunction with Epothilone B were analysed to 
determine whether the interaction between radiation and drug was additive or synergistic. 
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According to Luttjeboer (Luttjeboer et al. 2010), for two combined treatments, i.e. drug and radiation, it is 
possible to identify an additivity region in the dose-effect plane, bounded by two survival curves calculated 
for two different additivity mechanisms, i.e, “independent”and “overlapping”. In the first case it is supposed 
that  drug and radiation act independently, therefore survival after the combined treatment is calculated as the 
product of the survival values relative to the single treatments. For “overlapping” additivity  the drug is 
supposed to act as an additional radiation dose, D*. D* is calculated as the dose giving the same cytotoxicity 
induced by the drug alone. A survival curve for the combined treatment located below this additivity region 
suggests the presence of a synergistic radiation-drug interaction.  
3. Results 
3.1 Epothilone B effects on clogenic survival  
The cells were exposed to Epothilone B concentrations between 0.05 nM and 0.6 nM, typical of a 
clinically achievable range of drug concentrations (Woltering et al. 2003). Fig.1 shows the clonogenic 
surviving fraction of A549 (circles) and U251MG cells (squares) as a function of  Epothilone B 
concentration. No effect occurred at concentrations lower than 0.05 nM and 0.075 nM for A549 and 
U251MG respectively thus suggesting the presence of a threshold concentration under which the drug 
has basically no effect on cell clonogenic survival. For concentrations greater than the threshold value, 
clonogenic survival decreases. A concentration corresponding to a surviving level of about 40%, was 
chosen to be used in conjunction with radiation. This concentration is equal to 0.075 nM for A549 cells 
and to 0.125 nM for U251MG. Results of the present study on A549 cells treated with Epothilone B at 
concentrations between 0,05 and 0.1 nM are similar to those found for clonogenic survival by Rohrer 
Bley (Rohrer Bley et al 2009 ) whereas results on U251MG cells at EpothiloneB  concentrations 
between 0.05 and 0.2nM are similar to those found by Furmanova-Hollenstein  (Furmanova-Hollenstein  
et al 2013 ). 
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Fig. 1 Surviving fraction of A549 () and U251MG (■) cells as a function of Epothilone B concentration. 
Error bars represent SE (SE = Standard Error). 
 
3.2. Clonogenic survival vs radiation dose and the effect of  Epothilone B . 
Figures 2 and 3 show survival data (mean of 4 independent experiments) of A549 and U251 cells 
exposed to (a) 6MV photons and (b) protons, alone (full symbols) or combined with Epothilone B 
(empty symbols). The curve relative to radiation alone is the fit to the experimental points according to 
the linear quadratic model, S = exp(-D-D2) (eq.1) with S = Survival and D = Dose.  
Data obtained for cells treated with Epothilone B show a different radiation dose-dependence. In fact, 
the surviving fraction decreases exponentially with dose, without any shoulder. Thus, data were fitted 
with a linear function S = S0 exp(-D) (eq.2), where the parameter S0 represents the clonogenic survival 
of cells treated with Epothilone B and not irradiated. The value obtained for the fit parameters are 
reported in Table 1. 
Comparing the curves relative to photon and proton irradiation alone, it is possible to notice that for 
both cell lines, protons are more effective than photons in inducing clonogenic cell death. Indeed 
survival values at 2 Gy (SF2Gy) with  A549 cells are 0.49 ± 0.05 and 0.25 ± 0.03 for photons and 
protons respectively, with U251MG cells SF2Gy results are 0.48 ± 0.05 and 0.25 ± 0.02 for photons and 
protons respectively. Protons Relative Biological Effectiveness (RBE) was calculated as the ratio 
between the dose of reference radiation (6MV photons) and that of protons necessary to produce the 
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same biological effect. At 10% of clonogenic survival the RBE of the CNAO proton beam (mid SOBP) 
resulted equal to 1.5 ± 0.2 for both the cell lines.  
For combined treatments with Epothilone B, protons effectiveness relative to combined treatments with 
photons can be evaluated as the ratio of the slopes of the two exponential survival curves (αp/αX). In this 
case, it did not depend on the survival level and its value was 1.3 ± 0.1 for both A549 and U251MG 
cells. 
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Fig. 2 Surviving fraction (mean of 4 independent experiments) of A549 cells exposed to (a) photon and (b) proton 
beams alone (●) and in combination with 0.075 nM Epothilone B (○). Solid lines are the fit of the experimental 
data according to eqs (1) or (2) for radiation alone or combined with Epothilone B respectively. Error bars 
represent SE (SE = Standard Error) 
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Fig.3 Surviving fraction (mean of 4 independent experiments) of U251MG cells exposed to (a) photon and (b) 
proton beams alone (●) and in combination with 0.125 nM Epothilone B (○). Solid lines are the fit of the 
experimental data according to eqs (1) or (2) for radiation alone or combined with Epothilone B respectively.  
Error bars represent SE (SE = Standard Error)  
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Table 1: Parameters of  Survival Curves 
Radiation  Cell line 
Radiation alone Radiation + Epothilone B 
α ± SE [Gy-1] β ± SE [Gy-2] S 0 ± SE α ± SE [Gy
-1
] 
photons 
A549 0.34 ± 0.04 0.028 ± 0.006 0.39 ± 0.03 0.70 ± 0.04 
U251MG 0.38 ± 0.04 0.028 ± 0.009 0.34 ± 0.02 0.82 ± 0.04 
protons 
A549 0.56 ± 0.07 0.05 ± 0.02 0.36 ± 0.03 0.89 ± 0.04 
U251MG 0.54 ± 0.05 0.07 ± 0.01 0.38 ± 0.03 1.06 ± 0.03 
 
Notes
 
α and β values were obtained from the fit of experimental data for radiation alone or in combination with 
Epothilone B according to eqs (1) or (2) respectively. S0 is the clonogenic survival of cells treated with Epothilone 
B alone. SE= Standard Error. 
 
3.3 Interaction between radiation and Epothilone B 
Figures 4 and 5 show the results of the analysis of radiation–drug interaction for A549 and U251MG cells, 
respectively. The experimental data relative to the combined treatment (CT) are compared with the curves 
calculated for independent (IA) and overlapping (OA) additivity of the two agents. 
The doses giving the same cytotoxicity as Epothilone B alone (S0), i.e. , D*, used to calculate the curves  
relative to overlapping additivity for A549 cells, were 2.3 and 1.6 Gy for photons and protons respectively. 
The correspondent values for U251MG cells were 2.4 and 1.5 Gy. 
For both the cell lines and both the radiation types, the experimental curves relative to the combined 
treatment fall below the additivity region bounded by the two calculated curves, thus indicating a 
synergism between the two agents, but the effect is more marked  for photons than protons. 
In order to quantify the effectiveness of the combined treatment compared with irradiation alone, the 
Dose Enhancement Factor (DEF) was evaluated. The DEF is defined as the ratio between the radiation 
doses used alone and in conjunction with the drug to obtain the same biological end point (i.e. the same 
survival level). For A549 cells, at 10% of survival, DEF resulted 1.5 ± 0.1 and 1.2 ± 0.1 for photons and 
protons respectively; for U251MG cells it resulted 1.6 ± 0.2 and 1.4 ± 0.1 for photons and protons, 
respectively. 
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Fig. 4 Analysis of radiation-drug interaction in A549 cells. Experimental data relative to photon (a) and proton (b) 
irradiation in conjunction with 0.075 nM Epothilone B are reported and fitted with the solid line (CT). The dashed line 
(IA) represents drug and radiation acting independently on cell survival. The dashed line (OA)is relative to the 
overlapping additivity.  
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Fig. 5 Analysis of radiation-drug interaction in U251 MG cells. Experimental data relative to photon (a) and proton (b) 
irradiation in conjunction with 0.125 nM Epothilone B are reported and fitted with the solid line (CT). The dashed line 
(IA) represents drug and radiation acting independently on cell survival. The dashed line (OA)is relative to the  
overlapping additivity.  
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4. Discussion  
We investigated the response of lung adenocarcinoma cells A549 and glioblastoma U251MG to 
irradiation with a SOBP proton beam alone and in combination  with Epothilone B. The same study was 
performed on a 6 MV photon beam. The results show that Epothilone B  has an anticlonogenic effect at 
subnanomolar concentrations in both A549 and U251MG cells and that its use modifies the response of 
these cells to photon and proton irradiation, removing the typical shoulder of the dose-survival curves 
found after treatment with radiation alone. The interaction modality between photons or protons and 
Epothilone B in A549 and U251MG cells is slightly synergistic. Our results with photon beam on A549 
cells are in agreement with those of Baumgart (Baumgart et al. 2012), who found for the same cell line a 
synergistic effect of Epothilone B used in combination with photon beams irradiation. Furthermore 
Roher-Bley (Roher-Bley et al 2009) and Roher-Bley (Roher-Bley et al 2013) found an at least additive 
effect of Epothilone B and X-rays on A549 cell line. Hofstetter (Hofstetter et al 2005) observed that 
Epothilone B has a radiosenziting effect in the human colon adenocarcinoma cell line SW480 and in 
p53-null MEF cells when combined with X-rays. Oehler (Oehler et al 2011) demonstrated that 
Epothilone B is a very effective cytotoxic agent against several medulloblastoma  cell lines, that it 
strongly reduces clonogenic survival alone and in conjunction with ionizing radiation at picomolar 
concentrations. It also resulted in an at least additive anticlonogenic effect  in combination with 
clinically relevant dose of X rays.  
As far as we know there are no published studies on the use of Epothilone B in combination with proton 
beam irradiation on A549 or U251MG cells. The results of the present study show that Epothilone B 
increases protons cytotoxicity with a synergism which is slightly weaker than that of photons , as shown 
by the DEF values, greater for photons than protons . This weaker synergism may be due to different 
amounts of reparable damages induced by the two radiation types  (greater for photons than protons). In 
fact, we found that proton RBE values at 10% of survival are 1.5 ± 0.2 for both A549 and U251MG 
cells. These RBE values are higher than 1.1, value which is conventionally used for therapeutic proton 
beams (ICRU report 2007). In vitro values of proton RBE from literature show significant variations as 
reported in some reviews (Paganetti 2014, Jones 2016). These RBE variations may be due to different 
experimental conditions (beam energy, active scanning techniques or passive beam modulation, methods 
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for RBE calculation, cell lines, reference radiation ). Furthermore data emerging from recent studies 
suggest that for several end points the biological response is differentially modulated by protons 
compared to photons (Tommasino and Durante 2015, Girdhani et al 2013). As shown by Girdhani 
(Girdhani et al 2013), several reports have suggested that at clinically relevant energies, protons can be 
more effective than photons to produce DSBs (DNA double-strand-breaks). Calugaru ( Calugaru et al 
2011) showed that the incidence of DSBs and clustered lesions was higher for protons than for 
137
CS 
gamma-rays. Britten (Britten et al 2013) measured RBE values for cell killing of Hep2 human laryngeal 
cancer cells at various positions along the depth dose profile of modulated proton therapy beams. The 
authors concluded that the RBE for human cancer cells in the mid-distal part of the SOBP is greater 
(1.5-2.1) than the widely used 1.1 value. Recently, Mitteer (Mitteer et al 2015) using glioma stem cells 
found that, compared to photons, proton beams induces greater DNA damage, cell cycle alteration and 
cytotoxicity through reactive oxygen species (ROS). The difference in the amount of correctly-reparable 
damage induced by photon or proton irradiation may explain not only the high proton RBE values found 
in the present study, but also the weaker synergism found for the interaction of protons, compared to 
photons, with Epothilone B. Indeed it was demonstrated (Baumgart et al 2012), (Baumgart et al 2015), 
that Epothilone B reduces DNA repair capability of tumour cells, a property which may be less relevant 
in the case of interaction of the drug with a radiation inducing less reparable lesions. Experiments on the 
interaction of Epothilone B with Carbon-ion beams which, compared with protons, induce even less 
reparable damage due to their higher ionization density, are in progress in our Laboratory to investigate 
this aspect. Despite the weak synergism, proton beams are very promising to be used in combination 
with a non tumour-specific drug (such as Epothilone B), due to their good conformability to the tumour 
volume. 
 
5. Conclusion 
In conclusion, our in vitro study shows that Epothilone B has a radiosensitizing effect in A549 and 
U251MG cells when combined with proton or photon beams, with a synergistic type of interaction with 
radiation. The results of the present study provide a radiobiological basis for further experiments and 
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suggest that the combination of Epothilone B with protontherapy could be tested in controlled phase I 
clinical trials in advanced NSCLC and GM patients as a new and promising tool  for treatment.  
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